Key result
Antihypertensive therapy trials typically reflect short-term perspectives, highlighting the need for long-term studies using surrogate endpoints to assess the prevention of cardiovascular lesions.
Answers are grounded in this paper and cite their sources.
Highlights the need for long-term trials using surrogate endpoints to assess the ability of antihypertensive drugs to prevent cardiovascular lesions in mild-to-moderate hypertension.
Randomized trials of antihypertensive therapy are relatively short in duration (3 to 5 years) and, when based on monitoring of the mortal and morbid events occurring during this period of time, represent short-term perspectives of antihypertensive therapy. In cases of mild-to-moderate hypertension, however, the goal of antihypertensive therapy is not the prevention of impending events but, rather, the avoidance or retardation of cardiovascular lesions. These long-term perspectives can only be explored by randomized trials that monitor surrogate endpoints (for example, left ventricular hypertrophy or atherosclerotic plaque development). In the future, more and more antihypertensive drugs will be tested to assess their ability to interfere with both cardiovascular disease and cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Alberto Zanchetti (1993) conducted an editorial in hypertension. Antihypertensive therapy was evaluated. Antihypertensive therapy trials typically reflect short-term perspectives, highlighting the need for long-term studies using surrogate endpoints to assess the prevention of cardiovascular lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: